Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/29216
Type
PreprintCopyright
Open access
Embargo date
2019-09-10
Collections
- INI - Preprint [99]
Metadata
Show full item record
AWARENESS, WILLINGNESS AND PREP ELIGIBILITY AMONG TRANSGENDER WOMEN IN RIO DE JANEIRO, BRAZIL
HIV
Pre-Exposure Prophylaxis
HIV Infections/prevention & control
Health Knowledge
Attitudes
Practice
Author
Jalil, Emilia M.
Grinsztejn, Beatriz
Velasque, Luciane
Makkeda, Alessandra Ramos
Luz, Paula Mendes
Moreira, Ronaldo I.
Kamel, Luciana
Fernandes, Nilo Martinez
Ferreira, Ana Cristina G.
Hoagland, Brenda Regina de Siqueira
Cardoso, Sandra Wagner
Liu, Albert
McFarland, Willi
Buchbinder, Susan
Veloso,Valdiléa G.
Wilson, Erin
Transcender Study Team
Grinsztejn, Beatriz
Velasque, Luciane
Makkeda, Alessandra Ramos
Luz, Paula Mendes
Moreira, Ronaldo I.
Kamel, Luciana
Fernandes, Nilo Martinez
Ferreira, Ana Cristina G.
Hoagland, Brenda Regina de Siqueira
Cardoso, Sandra Wagner
Liu, Albert
McFarland, Willi
Buchbinder, Susan
Veloso,Valdiléa G.
Wilson, Erin
Transcender Study Team
Affilliation
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Estado do Rio de Janeiro. Rio de Janeiro, RJ, Brasil.
Rio de Janeiro Federal Institute of Education, Science and Technology. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Bridge HIV, San Francisco Department of Public Health. USA.
Departments of Medicine, Epidemiology and Biostatistics, UCSF
Bridge HIV, San Francisco Department of Public Health./ Departments of Medicine, Epidemiology and Biostatistics, UCSF
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Bridge HIV, San Francisco Department of Public Health. USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Estado do Rio de Janeiro. Rio de Janeiro, RJ, Brasil.
Rio de Janeiro Federal Institute of Education, Science and Technology. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Bridge HIV, San Francisco Department of Public Health. USA.
Departments of Medicine, Epidemiology and Biostatistics, UCSF
Bridge HIV, San Francisco Department of Public Health./ Departments of Medicine, Epidemiology and Biostatistics, UCSF
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Bridge HIV, San Francisco Department of Public Health. USA.
Abstract
Background: HIV epidemics disproportionately affect transwomen worldwide. Trans-specific guidance, outreach, and interventions to increase pre-exposure prophylaxis (PrEP) use among transwomen are scarce.
Setting: Rio de Janeiro, Brazil. Methods: We measured awareness and willingness to use PrEP and examined factors associated with those outcomes among transwomen in Rio de Janeiro, and estimated how many transwomen would be eligible for PrEP. Data originate from Transcender study, a respondent-driven sampling survey conducted from August 2015 to January 2016. We performed regression models for PrEP awareness and willingness. Results: 131 (38.0%) out of 345 participants had heard of PrEP. Among transwomen who selfreported as HIV-negative, 162 (76.4%) out of 212 (with available data) reported willingness to use it and 163 (66.8%) out of 244 met behavioral eligibility criteria for PrEP. Transwomen with
health access in the prior six months, who reported HIV-infected sexual partner, and with 8+ years of schooling had increased odds of PrEP awareness. Lower PrEP awareness was associated with condomless anal intercourse and a newly diagnosed HIV-infection. Younger age and
perceiving themselves at risk of HIV-infection increased the odds of PrEP willingness. Lower odds of PrEP willingness was associated with concerns about long-term effects of PrEP and with difficulties in getting access to health care due to transphobia. Conclusion: Combination of low awareness, high willingness and substantial PrEP eligibility corroborates transwomen as a key-population for HIV prevention. PrEP is a promising and empowering strategy for HIV prevention among transwomen, but trans-specific
recommendations are needed to effectively implement PrEP in this population.
Keywords
Transgender personHIV
Pre-Exposure Prophylaxis
HIV Infections/prevention & control
Health Knowledge
Attitudes
Practice
Share